vs
Side-by-side financial comparison of KAMADA LTD (KMDA) and STEM, INC. (STEM). Click either name above to swap in a different company.
STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $47.0M, roughly 1.0× KAMADA LTD). KAMADA LTD runs the higher net margin — 11.3% vs -33.9%, a 45.2% gap on every dollar of revenue. On growth, KAMADA LTD posted the faster year-over-year revenue change (12.6% vs -15.6%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs 12.0%).
Kamada Ltd. is a global biopharmaceutical company specializing in the research, manufacturing, and commercialization of specialty pharmaceuticals derived from human plasma.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
KMDA vs STEM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.0M | $47.1M |
| Net Profit | $5.3M | $-16.0M |
| Gross Margin | 42.0% | 48.9% |
| Operating Margin | 16.6% | -17.7% |
| Net Margin | 11.3% | -33.9% |
| Revenue YoY | 12.6% | -15.6% |
| Net Profit YoY | 37.1% | 68.8% |
| EPS (diluted) | $0.09 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $47.1M | ||
| Q3 25 | $47.0M | $38.2M | ||
| Q2 25 | $44.8M | $38.4M | ||
| Q1 25 | $44.0M | $32.5M | ||
| Q4 24 | — | $55.8M | ||
| Q3 24 | $41.7M | $29.3M | ||
| Q2 24 | $42.5M | $34.0M | ||
| Q1 24 | $37.7M | $25.5M |
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $5.3M | $-23.8M | ||
| Q2 25 | $7.4M | $202.5M | ||
| Q1 25 | $4.0M | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | $3.9M | $-148.3M | ||
| Q2 24 | $4.4M | $-582.3M | ||
| Q1 24 | $2.4M | $-72.3M |
| Q4 25 | — | 48.9% | ||
| Q3 25 | 42.0% | 35.5% | ||
| Q2 25 | 42.3% | 33.4% | ||
| Q1 25 | 47.1% | 32.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | 41.3% | 21.2% | ||
| Q2 24 | 44.6% | 27.6% | ||
| Q1 24 | 44.4% | -95.0% |
| Q4 25 | — | -17.7% | ||
| Q3 25 | 16.6% | -33.6% | ||
| Q2 25 | 15.8% | -34.8% | ||
| Q1 25 | 17.7% | -65.0% | ||
| Q4 24 | — | -84.4% | ||
| Q3 24 | 12.7% | -493.2% | ||
| Q2 24 | 13.3% | -1705.5% | ||
| Q1 24 | 10.7% | -267.0% |
| Q4 25 | — | -33.9% | ||
| Q3 25 | 11.3% | -62.2% | ||
| Q2 25 | 16.5% | 527.8% | ||
| Q1 25 | 9.0% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | 9.3% | -506.3% | ||
| Q2 24 | 10.4% | -1712.6% | ||
| Q1 24 | 6.3% | -283.9% |
| Q4 25 | — | $-4.40 | ||
| Q3 25 | $0.09 | $-2.84 | ||
| Q2 25 | $0.13 | $-1.79 | ||
| Q1 25 | $0.07 | $-0.15 | ||
| Q4 24 | — | $-15.29 | ||
| Q3 24 | $0.07 | $-18.24 | ||
| Q2 24 | $0.08 | $-71.81 | ||
| Q1 24 | $0.04 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.0M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $265.2M | $-249.4M |
| Total Assets | $377.2M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $48.9M | ||
| Q3 25 | $72.0M | $43.1M | ||
| Q2 25 | $66.0M | $40.8M | ||
| Q1 25 | $76.3M | $58.6M | ||
| Q4 24 | — | $56.3M | ||
| Q3 24 | $72.0M | $75.4M | ||
| Q2 24 | $56.5M | $89.6M | ||
| Q1 24 | $48.2M | $112.8M |
| Q4 25 | — | $-249.4M | ||
| Q3 25 | $265.2M | $-235.7M | ||
| Q2 25 | $260.0M | $-214.1M | ||
| Q1 25 | $252.0M | $-417.5M | ||
| Q4 24 | — | $-398.4M | ||
| Q3 24 | $255.3M | $-344.1M | ||
| Q2 24 | $251.2M | $-203.2M | ||
| Q1 24 | $251.2M | $371.6M |
| Q4 25 | — | $308.9M | ||
| Q3 25 | $377.2M | $362.6M | ||
| Q2 25 | $368.2M | $379.2M | ||
| Q1 25 | $375.1M | $405.1M | ||
| Q4 24 | — | $437.4M | ||
| Q3 24 | $351.2M | $537.8M | ||
| Q2 24 | $351.0M | $691.5M | ||
| Q1 24 | $343.2M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.4M | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.97× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.2M | ||
| Q3 25 | $10.4M | $11.4M | ||
| Q2 25 | $8.0M | $-21.3M | ||
| Q1 25 | $-513.0K | $8.5M | ||
| Q4 24 | — | $-14.7M | ||
| Q3 24 | $22.2M | $-9.4M | ||
| Q2 24 | $14.0M | $-11.9M | ||
| Q1 24 | $1.0M | $-621.0K |
| Q4 25 | — | — | ||
| Q3 25 | 1.97× | — | ||
| Q2 25 | 1.09× | -0.11× | ||
| Q1 25 | -0.13× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.75× | — | ||
| Q2 24 | 3.15× | — | ||
| Q1 24 | 0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
